Ghady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, Christian Kollmannsberger, Naveen S Basappa, Anil Kapoor, Denis Soulières, Antonio Finelli, Daniel Y C Heng, Vincent Castonguay, Christina Canil, Eric Winquist, Jeffrey Graham, Georg A Bjarnason, Bimal Bhindi, Aly-Khan Lalani, Frédéric Pouliot, Rodney H Breau, Ramy Saleh, Simon Tanguay
BACKGROUND AND OBJECTIVE: Metastatic renal cell carcinoma (mRCC) patients have been reported to have better outcomes when treated with immunotherapies (IO) compared to targeted therapies (TT). This study aims to evaluate the impact of first-line systemic therapies on survival of mRCC patients with or without sarcomatoid features using real-world data. METHODS: Metastatic RCC patients of International mRCC Database Consortium (IMDC) intermediate or high risk, diagnosed from January 2011 to December 2022, treated with first-line systemic therapies, and with histological documentation of the presence or absence of sarcomatoid features in nephrectomy specimens were identified using the Canadian Kidney Cancer information system...
December 13, 2023: European Urology Oncology